Oncology News | pharmaphorum

Tuesday 26 May 2026

News

News

Datroway is first TROP2 drug for frontline breast cancer

Datroway is first TROP2 drug for frontline breast cancer

AZ and Daiichi's Datroway has been cleared by the FDA as first-line treatment for triple-negative breast cancer patients ineligible for immunotherapy.

News

Late-breakers to look out for at ASCO 2026

Late-breakers to look out for at ASCO 2026

ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.

News

A group of women hugging each other

NICE changes stance on Genmab's cervical cancer drug

After saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement authority NICE has had a change of heart.

News

Mathai Mammen

Tuneable peptide biotech Parabilis files IPO

Fresh from agreeing a wide-ranging alliance with Regeneron worth up to $2.3bn, Parabilis has joined the IPO queue.

News

Dr Domenica Lorusso

MSD's Sac-TMT delivers in first phase 3 readout

MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.

News

Novartis reveals more data behind Pluvicto expansion bid

Novartis reveals more data behind Pluvicto expansion bid

Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.